Adverum Biotechnologies, Inc. (ADVM)

9,72 +0,19 (+1,99%) Al cierre: 04:00PM EDT

Adverum Biotechnologies, Inc.

100 Cardinal Way
Redwood City, CA 94063
United States
650 656 9323
https://adverum.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 121

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Laurent Fischer	President, CEO & Director	1,02M	N/A	1964
Ms. Linda M. Rubinstein M.A.	CFO, Principal Financial Officer & Principal Accounting Officer	940,99k	N/A	1967
Mr. Kishor Peter Soparkar J.D.	Chief Operating Officer	674,98k	N/A	1972
Dr. Setareh Seyedkazemi Pharm.D.	Chief Development Officer	656,84k	N/A	1975
Dr. R. Andrew Ramelmeier Ph.D.	Chief Technology Officer	N/A	N/A	1962
Dr. Romuald Corbau Ph.D.	Chief Scientific Officer	N/A	N/A	1969
Mr. John W. Rakow J.D.	Senior VP & General Counsel	954,24k	N/A	1957
Ms. Dena House	Chief People Officer	N/A	N/A	N/A
Ms. Carla Fiankan	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A
Mr. Michael Steel	Senior Vice President of Quality	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Gobierno corporativo

El ISS Governance QualityScore de Adverum Biotechnologies, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.